239 related articles for article (PubMed ID: 26961773)
1. Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases.
Li Y; Pan W; Connolly ID; Reddy S; Nagpal S; Quake S; Gephart MH
J Neurooncol; 2016 May; 128(1):93-100. PubMed ID: 26961773
[TBL] [Abstract][Full Text] [Related]
2. Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies.
Momtaz P; Pentsova E; Abdel-Wahab O; Diamond E; Hyman D; Merghoub T; You D; Gasmi B; Viale A; Chapman PB
Oncotarget; 2016 Dec; 7(51):85430-85436. PubMed ID: 27863426
[TBL] [Abstract][Full Text] [Related]
3. Brain tumor mutations detected in cerebral spinal fluid.
Pan W; Gu W; Nagpal S; Gephart MH; Quake SR
Clin Chem; 2015 Mar; 61(3):514-22. PubMed ID: 25605683
[TBL] [Abstract][Full Text] [Related]
4. Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid.
White MD; Klein RH; Shaw B; Kim A; Subramanian M; Mora JL; Giobbie-Hurder A; Nagabhushan D; Jain A; Singh M; Kuter BM; Nayyar N; Bertalan MS; Stocking JH; Markson SC; Lastrapes M; Alvarez-Breckenridge C; Cahill DP; Gydush G; Rhoades J; Rotem D; Adalsteinsson VA; Mahar M; Kaplan A; Oh K; Sullivan RJ; Gerstner E; Carter SL; Brastianos PK
JAMA Netw Open; 2021 Aug; 4(8):e2120040. PubMed ID: 34369989
[TBL] [Abstract][Full Text] [Related]
5. Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease.
Ballester LY; Glitza Oliva IC; Douse DY; Chen MM; Lan C; Haydu LE; Huse JT; Roy-Chowdhuri S; Luthra R; Wistuba II; Davies MA
J Neuropathol Exp Neurol; 2018 Jul; 77(7):628-635. PubMed ID: 29873738
[TBL] [Abstract][Full Text] [Related]
6. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.
Gonzalez-Cao M; Mayo-de-Las-Casas C; Molina-Vila MA; De Mattos-Arruda L; Muñoz-Couselo E; Manzano JL; Cortes J; Berros JP; Drozdowskyj A; Sanmamed M; Gonzalez A; Alvarez C; Viteri S; Karachaliou N; Martin Algarra S; Bertran-Alamillo J; Jordana-Ariza N; Rosell R
Melanoma Res; 2015 Dec; 25(6):486-95. PubMed ID: 26366702
[TBL] [Abstract][Full Text] [Related]
7. Tumor DNA Mutations From Intraparenchymal Brain Metastases Are Detectable in CSF.
Cheok SK; Narayan A; Arnal-Estape A; Gettinger S; Goldberg SB; Kluger HM; Nguyen D; Patel A; Chiang V
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250381
[TBL] [Abstract][Full Text] [Related]
8. A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma.
Law V; Chen Z; Vena F; Smalley I; Macaulay R; Evernden BR; Tran N; Pina Y; Puskas J; Caceres G; Bayle S; Johnson J; Liu JKC; Etame A; Vogelbaum M; Rodriguez P; Duckett D; Czerniecki B; Chen A; Smalley KSM; Forsyth PA
Neuro Oncol; 2022 Oct; 24(10):1673-1686. PubMed ID: 35213727
[TBL] [Abstract][Full Text] [Related]
9. Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.
Santiago-Walker A; Gagnon R; Mazumdar J; Casey M; Long GV; Schadendorf D; Flaherty K; Kefford R; Hauschild A; Hwu P; Haney P; O'Hagan A; Carver J; Goodman V; Legos J; Martin AM
Clin Cancer Res; 2016 Feb; 22(3):567-74. PubMed ID: 26446943
[TBL] [Abstract][Full Text] [Related]
10. Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report.
Kim DW; Barcena E; Mehta UN; Rohlfs ML; Kumar AJ; Penas-Prado M; Kim KB
BMC Cancer; 2015 May; 15():400. PubMed ID: 25962795
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
Ascierto PA; Minor D; Ribas A; Lebbe C; O'Hagan A; Arya N; Guckert M; Schadendorf D; Kefford RF; Grob JJ; Hamid O; Amaravadi R; Simeone E; Wilhelm T; Kim KB; Long GV; Martin AM; Mazumdar J; Goodman VL; Trefzer U
J Clin Oncol; 2013 Sep; 31(26):3205-11. PubMed ID: 23918947
[TBL] [Abstract][Full Text] [Related]
12. [Cerebral magnetic resonance imaging (MRI) in the diagnosis of leptomeningeal carcinomatosis in melanoma patients].
Dupuis F; Sigal R; Margulis A; Mercier S; Spatz A; Mamelle G; Lartigau E; Duvillard P; Avril MF
Ann Dermatol Venereol; 2000 Jan; 127(1):29-32. PubMed ID: 10717559
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma.
Sakji-Dupré L; Le Rhun E; Templier C; Desmedt E; Blanchet B; Mortier L
Melanoma Res; 2015 Aug; 25(4):302-5. PubMed ID: 25933211
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
[TBL] [Abstract][Full Text] [Related]
15. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
[TBL] [Abstract][Full Text] [Related]
16. Recurrently Mutated Genes Differ between Leptomeningeal and Solid Lung Cancer Brain Metastases.
Li Y; Liu B; Connolly ID; Kakusa BW; Pan W; Nagpal S; Montgomery SB; Hayden Gephart M
J Thorac Oncol; 2018 Jul; 13(7):1022-1027. PubMed ID: 29604399
[TBL] [Abstract][Full Text] [Related]
17. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR.
Reid AL; Freeman JB; Millward M; Ziman M; Gray ES
Clin Biochem; 2015 Oct; 48(15):999-1002. PubMed ID: 25523300
[TBL] [Abstract][Full Text] [Related]
18. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
[TBL] [Abstract][Full Text] [Related]
19. Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient.
Wu RC; Newman W; Patanowitz L; Branstetter BF; Amankulor N; Tarhini AA
Immunotherapy; 2020 Aug; 12(11):763-769. PubMed ID: 32571131
[No Abstract] [Full Text] [Related]
20. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
